Gene delivery aimed at myelin-making brain cells for Canavan disease and related leukodystrophies
Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and Leukodystrophies
A gene-delivery approach that directs a corrective ASPA gene to the brain's myelin-producing cells to help people with Canavan disease and similar leukodystrophies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-11262311 on NIH RePORTER |
What this research studies
This research is developing a safer form of AAV gene therapy that uses a promoter copied from the ASPA gene so the corrective gene is mostly turned on in oligodendrocytes, the brain cells that make myelin. The team will test how well these vectors reach and work in oligodendrocytes using lab experiments and animal models, while checking for reduced off-target effects that have caused problems in prior AAV therapies. The project also studies how the ASPA promoter is regulated to improve precision and reduce toxicity. Findings could guide future clinical testing and may apply to other diseases where oligodendrocytes are involved.
Who could benefit from this research
Good fit: People with genetically confirmed Canavan disease or closely related leukodystrophies caused by ASPA deficiency would be the primary candidates for future trials based on this work.
Not a fit: People without ASPA-related leukodystrophy, or those whose disease is caused by unrelated genes or is too advanced for gene replacement, are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this could deliver the corrective ASPA gene more safely to the right brain cells, lowering harmful side effects and improving the chance of functional benefit for people with Canavan disease.
How similar studies have performed: AAV gene therapy has produced major successes (for example, Zolgensma for SMA) but has also revealed safety problems from widespread expression, and using an oligodendrocyte-specific promoter for Canavan is a novel strategy to reduce those risks.
Where this research is happening
Worcester, United States
- Univ of Massachusetts Med Sch Worcester — Worcester, United States (Active)
Researchers
- Principal investigator: Gao, Guangping — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Gao, Guangping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.